HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inter Parfums projections for 2008

This article was originally published in The Rose Sheet

Executive Summary

Net sales for the firm will reach approximately $437 mil. in fiscal year 2008, Inter Parfums says Nov. 28. That figure is 15.6% ahead of the firm's guidance of $378 mil. for 2007. Projected growth is based on a strong launch schedule in Europe, including the debut of The Beat, the sixth fragrance from the company's Burberry brand. Inter Parfums also will introduce Love and Heart, two Roxy fragrances for women, alongside launches for its Quicksilver, Van Cleef & Arpels, Paul Smith and S.T. Dupont brands, according to firm Chairman and CEO Jean Madar. In the U.S., Inter Parfums will continue its shift away from the mass market, offering new products and brand expansions to its specialty retail partners. "We are also hopeful that the first new products for Brooks Brothers' U.S. stores will be on the market before 2008 year-end," Madar notes. Sales growth for the year is expected to exceed net income growth due to the weakness of the U.S. dollar as well as staff and infrastructure investments in support of the firm's specialty retail initiative, according to Executive VP and CFO Russell Greenberg...

You may also be interested in...



Tiofarma Admits Involvement On UK Fludrocortisone

Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.

UK-Based GMDN Endorsed As US Preferred Method For Categorizing High-Risk Implants

While the EU has selected the CND system as the basis for its nomenclature, GMDN is becoming increasingly valued on the US and international scene. How does it see its latest role panning out globally?

UsernamePublicRestriction

Register

RS015107

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel